Periodic Reporting for period 3 - DELTA (AI Enabled Managemement of Patients at Risk of Diabetic Foot Ulcer)
Reporting period: 2022-03-01 to 2022-11-30
The objectives of this project were to complete product development of both the hardware and software components of the system, achieve regulatory approvals to market the product, and to commence pilot activities to generate real-world data regarding the product. All of this has been complete. Alongside these milestones the commercial strategy has been developed.
At completion of this project Bluedrop Medical is in a position to aggressively target the huge market for diabetic foot ulcer prevention and provide real impact to both patients and healthcare systems around the world.
We have grown our medical advisory board to include influential clinicians and experts in clinical research. This Medical Advisory Board has assisted with the drafting of Instructions For Use documents, pilot study protocols and monitoring protocols.
In addition to product development, regulatory and clinical activities. We have conducted commercial activities involving the expansion of our IP portfolio to new regions and conducting a health economic benefit analysis. We have engaged with further potential distribution partners as well as continuing to work with existing partners.